The Role of Partially Hydrolyzed Whey Formula for the Prevention of Allergic Disease

Evidence and Gaps

Adrian J Lowe; Shyamali C Dharmage; Katrina J Allen; Mimi LK Tang; David J Hill


Expert Rev Clin Immunol. 2013;9(1):31-41. 

In This Article

Five-year View

Given the long history of controversy concerning the role of pHWF for the prevention of allergic disease, it appears likely that this will remain the case for the next 5 years. Formula studies have major logistical issues, and are open to a range of potential bias including difficulty in blinding the distinct smell of each formula. New developments to improve the quality of formula trials are required to obtain definitive evidence on their role in preventing allergic disease. If this is not possible, alternate new approaches for prevention should be explored such as early introduction of allergen. In the next 5 years, trial-based evidence relating to the effect of allergen exposure in early life (4–6 months of age) will emerge and elucidate the role of early life exposure to intact allergens on the development of allergic disease.